The tumor immune composition of mismatch repair deficient and Epstein-Barr virus-positive gastric cancer: A systematic review
-
Published:2024-06
Issue:
Volume:127
Page:102737
-
ISSN:0305-7372
-
Container-title:Cancer Treatment Reviews
-
language:en
-
Short-container-title:Cancer Treatment Reviews
Author:
Bos J.ORCID,
Groen-van Schooten T.S.,
Brugman C.P.,
Jamaludin F.S.,
van Laarhoven H.W.M.,
Derks S.
Funder
Servier
Bristol-Myers Squibb
Reference162 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J Clin,2021
2. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer;Allum;Crit Rev Oncol Hematol,2018
3. Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: The METGastric randomized clinical trial;Shah;JAMA Oncol,2017
4. Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial;Fuchs;Lancet Oncol,2019
5. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V25 study group;Van Cutsem;J Clin Oncol,2006